Search

Your search keyword '"Nowakowski G"' showing total 49 results
Start Over Author "Nowakowski G" Search Limiters Academic (Peer-Reviewed) Journals
49 results on '"Nowakowski G"'

1. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

Author

Castellino, A., Chiappella, A., LaPlant, B. R., Pederson, L. D., Gaidano, G., Macon, W. R., Inghirami, G., Reeder, C. B., Tucci, A., King, R. L., Congiu, A., Foran, J. M., Pavone, V., Rivera, C. E., Spina, M., Ansell, S. M., Cavallo, F., Molinari, A. L., Ciccone, Giovannino, Habermann, T. M., Witzig, T. E., Vitolo, U., and Nowakowski, G. S.

Published
2018
Full Text
View/download PDF

5. CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.

Author

Munoz, J., Hoffmann, M., Westin, J., Vassilakopoulos, T. P., García‐Sancho, A. M., Rueda‐Domínguez, A., Jurczak, W., Kwiatek, M., Bouzani, M., Gkasiamis, A., Patel, A., Boucaud, F., Li, J., and Nowakowski, G. S.

Subjects
ANTINEOPLASTIC combined chemotherapy protocols, LYMPHOMAS, NON-Hodgkin's lymphoma
Abstract

CC-99282 plus R-CHOP in patients (pts) with previously untreated aggressive B-cell lymphoma (a-BCL): early safety and efficacy results from a phase 1b study CC-220-DLBCL-001 (NCT04884035) is an open-label, multicenter, dose-escalation and expansion trial to assess safety and preliminary efficacy of CC-99282 or CC-220 plus R-CHOP for untreated a-BCL. B Introduction: b Up to 30-40% of pts with diffuse large BCL relapse/become refractory after first-line chemo-immunotherapy with R-CHOP. [Extracted from the article]

Published
2023
Full Text
View/download PDF

6. Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL).

Author

Wang, Y., Larson, M. C., Ekberg, S., Smedby, K. E., Zhao, E. J., Gerrie, A. S., Farooq, U., Maurer, M. J., Paludo, J., Nowakowski, G. S., Habermann, T. M., Albertsson‐Lindblad, A., Glimelius, I., Link, B. K., Diego, V., Jerkeman, M., and Cerhan, J. R.

Subjects
MANTLE cell lymphoma, AFTERLIFE
Abstract

However, in Era M2, patients achieving EFS24 had similar OS compared to the general population (SMR = 1.35, 95% CI: 0.83-2.09), and lymphoma was no longer the leading cause of death (Figure 1 B&E). Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL) In Era M1, patients achieving EFS24 still had inferior OS compared to the general population (SMR = 2.81, 95% CI: 1.98-3.88), and lymphoma remained the leading cause of death. [Extracted from the article]

Published
2023
Full Text
View/download PDF

7. Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes.

Author

Bock, A. M., Mwangi, R., Wang, Y., Khurana, A., Maurer, M. J., Ayers, A., Kahl, B., Martin, P., Cohen, J., Casulo, C., Lossos, I., Farooq, U., Ayyappan, S., Reicks, T., Habermann, T. M., Flowers, C. R., Cerhan, J. R., Nastoupil, L. J., and Nowakowski, G. S.

Subjects
DIFFUSE large B-cell lymphomas, SURVIVAL rate
Abstract

Defining Primary Refractory Diffuse Large B-cell Lymphoma (DLBCL) Based on Survival Outcomes B Background: b DLBCL that fails to achieve a complete response (CR) or relapses early after standard immunochemotherapy (IC, e.g., R-CHOP or similar) is referred to as primary refractory DLBCL (prDLBCL) and has a poor prognosis. Patients with PD had significantly lower CR/PR rates (19.6%/19.6%) to second line therapy compared to patients with EOT PR (32.1%/30.4%) or early relapse (50.6%/19.1%)( I P i < 0.001). [Extracted from the article]

Published
2023
Full Text
View/download PDF

15. Effect of operating conditions on the performance of two-bed closed-cycle solid-sorption heat pump systems

Author

Zheng, W., Worek, W.M., and Nowakowski, G.

Subjects
Heat pumps -- Evaluation, Engineering and manufacturing industries, Environmental issues
Abstract

The effect of two operating parameters, the regeneration temperature and the ambient temperature, on the performance of two-bed, closed-cycle solid-sorption heat pumps is investigated. The results show that increasing the regeneration temperature can improve both the COP and cooling capacity, and the effect on cooling capacity is more significant than the COP. Increasing the regeneration temperature from 180 [degrees] C to 260 [degrees] C, the cooling capacity increases by 50 percent and the COP improves 20 percent. When the ambient temperature drops, the system performance increases significantly. When the ambient temperature decreases by 10 [degrees] C from the design point of 35 [degrees] C, the COP and cooling capacity increases by 50 percent and 40 percent, respectively. Also, the bed cycling speed should be increased to achieve the optimum system performance when the regeneration temperature is higher or the ambient temperature becomes lower.

Published
1995

16. Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL).

Author

Shreve, J. T., Hazim, A. Z., Bock, A. M., Pritchett, J. C., Maurer, M. J., Shah, M. V., Binder, M., Witzig, T. E., Wang, Y., Nowakowski, G. S., Novak, A. J., Young, J. R., Cerhan, J. R., Habermann, T. M., Ansell, S. M., and Paludo, J.

Subjects
DIFFUSE large B-cell lymphomas, RADIOMICS, CONVOLUTIONAL neural networks
Abstract

Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B-cell lymphoma (DLBCL) B Conclusion: b Radiomics features automatically extracted from pre-treatment PET/CT scans of DLBCL patients were associated with event free survival and appear to be promising prognostic markers, but will need external validation. B Introduction: b Pre-treatment PET/CT scans have not yet been incorporated into risk stratification models despite being the imaging modality of choice in DLBCL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

17. Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL).

Author

Bock, A. M., Mwangi, R., Ataei, F., Thorpe, M., Shreve, J. T., Pritchett, J. C., Maurer, M. J., Paludo, J., Cerhan, J. R., Khurana, A., Witzig, T. E., Habermann, T. M., Wang, Y., Nowakowski, G. S., and Young, J. R.

Subjects
DIFFUSE large B-cell lymphomas, SURVIVAL rate, TREATMENT effectiveness
Published
2023
Full Text
View/download PDF

33. PRE‐TREATMENT HEMOGLOBIN AND OUTCOME IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH ANTHRACYCLINE CONTAINING CHEMOTHERAPY.

Author

Clausen, M.R., Maurer, M., Ulrichsen, S.P., Larsen, T.S., Himmelstrup, B., Ronnov‐Jessen, D., Link, B., Feldman, A., Slager, S., Nowakowski, G., Thompson, C., Pedersen, P.T., Madsen, J., Pedersen, R.S., Gørløv, J.S., Cerhan, J.R., and d'Amore, F.

Subjects
DIFFUSE large B-cell lymphomas, HEMOGLOBINS, LYMPHOMAS, CANCER chemotherapy, MOLECULAR epidemiology
Published
2019
Full Text
View/download PDF

34. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO.

Author

Leonard, J.P., Trněny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L.M., Scheinberg, P., Flinn, I.W., Moreira, C., Tabah, A., Abouzaid, S., Kalambakas, S., Fustier, P., and Wu, C.

Subjects
QUALITY of life, RITUXIMAB
Published
2019
Full Text
View/download PDF

35. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO.

Author

Gribben, J., Trneny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S., Fustier, P., Wu, C., and Leonard, J.

Subjects
THERAPEUTICS, RITUXIMAB, PLACEBOS, STOCK ownership
Published
2019
Full Text
View/download PDF

36. Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy

Author

Clausen MR, Maurer MJ, Ulrichsen SP, Larsen TS, Himmelstrup B, Rønnov-Jessen D, Link BK, Feldman AL, Slager SL, Nowakowski GS, Thompson CA, Pedersen PT, Madsen J, Pedersen RS, Gørløv JS, Cerhan JR, Nørgaard M, and D'Amore F

Subjects
diffuse large b-cell lymphoma, hemoglobin, prognosis, nccn-ipi, Infectious and parasitic diseases, RC109-216
Abstract

Michael R Clausen,1 Matthew J Maurer,2 Sinna Pilgaard Ulrichsen,3 Thomas S Larsen,4 Bodil Himmelstrup,5 Dorthe Rønnov-Jessen,6 Brian K Link,7 Andrew L Feldman,8 Susan L Slager,2 Grzegorz S Nowakowski,9 Carrie A Thompson,9 Per Trøllund Pedersen,10 Jakob Madsen,11 Robert S Pedersen,12 Jette Sønderskov Gørløv,13 James R Cerhan,2 Mette Nørgaard,1 Francesco D’Amore1 1Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 4Department of Hematology, Odense University Hospital, Odense, Denmark; 5Department of Hematology, Zealand University Hospital, Roskilde, Denmark; 6Department of Hematology, Sygehus Lillebaelt, Vejle, Denmark; 7Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; 8Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 9Department of Medicine, Mayo Clinic, Rochester, MN, USA; 10Department of Hematology, Sydvestjysk Sygehus, Esbjerg, Denmark; 11Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; 12Department of Hematology, Hospitalsenheden Vest, Holstebro, Denmark; 13Department of Hematology, Rigshospitalet, Copenhagen, DenmarkCorrespondence: Michael R ClausenDepartment of Hematology, Aarhus University Hospital, Palle Juul-Jensens Blvd 35, Aarhus, DenmarkEmail mrc@clin.au.dkBackground: Hemoglobin (Hgb) concentration at diagnosis is associated with outcome in cancer. In a recently reported simplified 3-factor prognostic score in Hodgkin lymphoma, Hgb, along with age and clinical stage, outperformed the classical International Prognostic Score with seven parameters.Methods: In the present study, we investigated if pretherapeutic Hgb concentration added prognostic information to the NCCN-IPI in diffuse large B-cell lymphoma. We included patients from the Danish Lymphoma Registry (LYFO; N = 3499) and from the Molecular Epidemiology Resource (MER; N = 1225), Mayo Clinic and University of Iowa. Four sex-specific Hgb groups were defined: below transfusion threshold, from transfusion threshold to below lower limit of normal, from lower limit of normal to the population mean, and above the mean. We used multivariable Cox regression to estimate the hazard rate ratios (HR) and 95% CIs for overall survival (OS) and event-free survival (EFS), adjusting for sex, NCCN-IPI, comorbidity, and rituximab treatment.Results: Approximately half of the patients had Hgb levels below the lower limit of normal. Compared to patients with Hgb levels above the mean, an inferior OS was directly correlated with lower pretreatment Hgb within the predefined groups (HR=1.23, HR=1.51, and HR=2.05, respectively). These findings were validated in the MER.Conclusion: Based on multivariable analysis, lower pretreatment Hgb, even within the normal range but below the mean, added prognostic information to established indices such as the NCCN-IPI and the Charlson comorbidity index.Keywords: diffuse large B-cell lymphoma, hemoglobin, prognosis, NCCN-IPI

Published
2019

46. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS.

Author

Leonard, J., Trneny, M., Izutsu, K., Fowler, N., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S., Fustier, P., Wu, C., and Gribben, J.

Subjects
RITUXIMAB, PLACEBOS
Published
2019
Full Text
View/download PDF

48. Pulmonary langerhans cell histiocytosis

Author

Suri Harpreet S, Yi Eunhee S, Nowakowski Gregorz S, and Vassallo Robert

Subjects
Cigarette smoke, Interstitial, Bronchiolitis, Langerhans cells, Pulmonary hypertension, Medicine
Abstract

Abstract Pulmonary Langerhans Cell Histiocytosis (PLCH) is a relatively uncommon lung disease that generally, but not invariably, occurs in cigarette smokers. The pathologic hallmark of PLCH is the accumulation of Langerhans and other inflammatory cells in small airways, resulting in the formation of nodular inflammatory lesions. While the overwhelming majority of patients are smokers, mechanisms by which smoking induces this disease are not known, but likely involve a combination of events resulting in enhanced recruitment and activation of Langerhans cells in small airways. Bronchiolar inflammation may be accompanied by variable lung interstitial and vascular involvement. While cellular inflammation is prominent in early disease, more advanced stages are characterized by cystic lung destruction, cicatricial scarring of airways, and pulmonary vascular remodeling. Pulmonary function is frequently abnormal at presentation. Imaging of the chest with high resolution chest CT scanning may show characteristic nodular and cystic abnormalities. Lung biopsy is necessary for a definitive diagnosis, although may not be required in instances were imaging findings are highly characteristic. There is no general consensus regarding the role of immunosuppressive therapy in smokers with PLCH. All smokers must be counseled on the importance of smoking cessation, which may result in regression of disease and obviate the need for systemic immunosuppressive therapy. The prognosis for most patients is relatively good, particularly if longitudinal lung function testing shows stability. Complications like pneumothoraces and secondary pulmonary hypertension may shorten life expectancy. Patients with progressive disease may require lung transplantation.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results